Only very few of China's familiar diversified pharmaceutical firms are listed on NASDAQ or on OTC markets and directly accessible to U.S. investors
BeiGene
The pharmaceutical majors (excluding Sinovac Life Sciences, enmeshed in legal proceedings and delisted) hardly represent the entire Chinese healthcare sector of thousands of manufacturers
By way of reference, for comparison with promising biopharmaceuticals and with much higher valued Western counterparts, the available listings should still be informative
The companies - with state firm Sinopharm
Likely to remain the favored gateway for distribution of foreign medication in China, the China pharmaceutical firms, partnerships inked with international firms might be game changers
Loosely traded on OTC markets, the shares performance will usually reflect the trend but not the actual performance on their home market, adjusted for currency shifts - their track record on OTC is strictly informative and might justify further research
Depending on trading volume on U.S. OTC markets for the listed shares, performance, volatility and drawdown calculations will be affected - these ratios may not reflect true performance, volatility and drawdown as these same shares are normally traded on their national exchange
Our platform of asset information will include fundamental data information for companies listed on NYSE or NASDAQ, but accounting data for the OTC (over-the-counter) quoted firms is not avaliable
To highlight momentum and check trends, selected a short time frame - from two weeks to six months - on the menu (top right)
Investors are free to bookmark stocks of interest and to test investments in their virtual portfolio
